- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
+0.64| Last Update: 06/18/13 - 4:02 PM EDT |
| Volume: 2,621,480 |
| YTD Performance: 22.59% |
| Open: $59.39 |
| Previous Close: $59.27 |
| 52 Week Range: $43.65 - $60.70 |
| Oustanding Shares: 1,224,392,685 |
| Market Cap: 72,275,900,196 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $0.96 | $0.97 | $3.97 | $4.41 |
| Number of Analysts | 11 | 10 | 12 | 12 |
| High Estimate | $0.98 | $1.01 | $4.00 | $4.52 |
| Low Estimate | $0.93 | $0.94 | $3.92 | $4.20 |
| Prior Year | $0.81 | $0.85 | $3.44 | $3.97 |
| Growth Rate (Year over Year) | 18.07% | 14.35% | 15.36% | 11.19% |
Think in the short-term.
Companies catering to the high-end consumer are in favor.
CVS Investor Mtg. CVS Caremark Corporation Annual Shareholder Meeting - 8:30AM
For Walgreen, 2012's bad news was good news, while CVS remains an attractive investment choice.
CVS Caremark price target and estimates increased at UBSCVS earnings estimates were increased, said UBS. Health reform and generics will benefit the company in 2014/2015. Price target is now $60.
Stocks that defy correction and those ripe for correction.
CVS Caremark numbers increased at GuggenheimCVS estimates were raised through 2014, Guggenheim said. Company boosted its guidance. Buy rating and new $60 price target.
Short-term traders will likely give the benefit of the doubt to the bulls.
JP Morgan Healthcare Conf.
CVS Caremark numbers increased at JefferiesCVS estimates were raised through 2014, Jefferies said. Company can expand margins and repurchase more shares. Buy rating and new $58 price target.